Detalles de la búsqueda
1.
When cardiomyopathy, cancer, and COVID-19 collide: A case report.
Breast J
; 27(4): 384-386, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33527538
2.
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.
Breast Cancer Res Treat
; 149(1): 69-79, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25491778
3.
Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance).
Epigenetics
; 17(12): 1715-1725, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35412430
4.
A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.
Clin Breast Cancer
; 22(1): 32-42, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34158245
5.
Use of perioperative chemotherapy in colorectal cancer metastatic to the liver.
Gastroenterol Rep (Oxf)
; 7(5): 301-311, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31687149
6.
Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Clin Breast Cancer
; 19(2): e283-e296, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30737173
7.
Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.
J Natl Cancer Inst
; 115(11): 1240-1242, 2023 11 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37480258
8.
BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series.
JCO Precis Oncol
; 6: e2200091, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35834759
9.
A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Cancer Res
; 74(1): 15-23, 2014 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24322983
Resultados
1 -
9
de 9
1
Próxima >
>>